glp 1 news today Why GLP-1 drugs are changing the future of metabolic health FDA priority vouchers for GLP-1

Alternative form of glucose-dependent insulinotropic polypepide and its physiology

Caruso I, Cignarelli A, Sorice GP, Natalicchio A, Perrini S, Laviola L, et al

Jump to: What Kind Patches claims to do | The science behind transdermal delivery | Ingredient analysis | Why GLP-1 patches is misleading | Cost and value assessment | UK regulatory concerns | Evidence-based alternatives | Take home message There is no evidence that Kind Patches work to support weight loss

Comparison of the Cardiorenal Effects between Combination Therapy and Monotherapy with SGLT2i or GLP1RA

Our team has also shown increased GLP-1 RA prescribing (Gratzl et al., 2024)

Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease